http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Acute Cholecystitis After a Colonoscopy
박태익,이상용,이준희,김민철,김봉갑,차동혁 대한대장항문학회 2013 Annals of Coloproctolgy Vol.29 No.5
Acute cholecystitis after a colonoscopy is a rare event, and only eight documented cases are reported in the literature. A 35-year-old male underwent a screening colonoscopy. There was a 5-mm sessile polyp in the sigmoid colon, which was removed by using a hot snare polypectomy. Forty-eight hours after the colonoscopy, the patient visited our emergency department with epigastric pain and fever. Based on the clinical findings, laboratory data and radiologic imaging, our diagnosis was acute cholecystitis. Because no previous cases of this type have been reported to date in Korea, we publish the details of our patients who presented with a postcolonoscopy complication diagnosed as acute cholecystitis.
결핵성 복막염으로 오인되었으나 복강경으로 진단한 복막 중피종 1예
박태익,황종호,김산,조우성,차동혁,박수범,김형욱,강대환,최철웅 대한내과학회 2011 대한내과학회 추계학술대회 Vol.2011 No.1
중피종은 장막에 발생하는 드문 종양으로 흉막, 복막 드물게 심낭, 고환초막 등에서 발생할 수 있다. 복막 중피종은 흉막 중피종 다음을 차지하는 빈도로 발생하며 중피종의 20-30%를 차지한다. 매우 빠른 진행을 보이며 치료하지 않을 경우 평균 생존기간은 1년 미만인 예후가 나쁜 질환이다. 석면에 대한 노출력이 복막 중피종의 가장 중요한 위험 인자이나 석면 노출력이 없이 발생하는 경우도 보고되고 있다. 임상증상은 복수에 의한 복부팽만, 복통, 체중감소 등 비특이적 증상들로 발현되며 드물게 발열, 장폐쇄에 의한 합병증 등이 나타날 수 있다. 영상학적인 진단법만으로는 복강 내 고형 암의 복막 전이, 결핵성 복막염 등과 감별이 쉽지 않으며 조직 생검 및 면역조직화학염색을 통한 확진이 가능하다. 치료로는 절제술, 전신 화학요법, 복강내 화학요법, 복부 방사선 치료등이 시도되고 있다. 복막 중피종은 드문 유병률을 가진 질환으로 정확한 병력 청취와 첫 감별 진단에서 의심을 가지고 접근하지 않으면 진단이 쉽지 않으며, 국내와 같이 결핵의 유병률이 높은 지역에서는 감별 진단에 더욱 유의하여야 한다. 과거 결핵 병력이 있으며 원인 미상의 복수를 주소로 타병원 내원하여 경험적인 항결핵치료를 받던 중 호전이 없어 본원으로 전원되어 복강경을 통한 조직 검사를 통해 복막 중피종을 진단한 증례를 경험하였기에 문헌고찰과 함께 보고한다.
박태익 ( Tae Ik Park ),김표준 ( Pyo Jun Kim ),김광하 ( Gwang Ha Kim ),강대환 ( Dae Hwan Kang ),송근암 ( Geun Am Song ),김영규 ( Young Kyu Kim ),이호석 ( Ho Seok I ) 대한내과학회 2008 대한내과학회지 Vol.75 No.4
저자들은 내원 2일 전 갑자기 발생한 삼킴 곤란, 흉부 불쾌감으로 내원한 환자에서 출혈이 합병된 식도 중복 낭종을 진단하고, 성공적인 절제술 후 특별한 부작용 없이 회복한 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Esophageal duplication is a rare congenital disorder. Although infrequent, complications such as infection, bleeding, and perforation have been reported. Surgical resection is the standard treatment for esophageal duplication cysts. We report the case of a 45-year-old female with an esophageal duplication cyst that presented with dysphagia, with a review of the literature.(Korean J Med 75:444-448, 2008)
김준,박태익,안성규,이한철,김준홍,전국진,홍택종,신영우 대한심장학회 2008 Korean Circulation Journal Vol.38 No.1
An electrical storm is defined as multiple occurrences of ventricular tachycardia/fibrillation (VT/VF) within a single day; this is a medical emergency and a poor prognostic marker in patients with an implantable cardioverter-defibrillator (ICD). We report here on the occurrence of electrical storms in a 35-year-old man with a repaired DCRV and ICD. He had recurrent VT and electrical storms that were refractory to amiodarone and β-blocker. A cardiac electrophysiologic study was performed 11 months after the ICD was implanted and two forms of VT were induced. After the catheter ablation of the VTs, the monomorphic VT became non-inducible. The frequency of the VT decreased from 35 per month before the catheter ablation to 1.1 times per month after the procedure. Catheter ablation of VT could be an effective treatment for patients with electrical storms refractory to antiarrhythmic drugs. (Korean Circ J 2008;38:60-65)
급성 심근경색증 환자에서 관동맥 중재 시술 전에 관동맥 내 Nicorandil 투여 효과
안성규,박태익,황기원,최재훈,이태근,이한철,김준,김준홍,홍택종,신영우,전국진 대한심장학회 2008 Korean Circulation Journal Vol.38 No.2
Background and Objectives: Intravenous nicorandil infusion with percutaneous coronary intervention (PCI) has been reported to reduce reperfusion injury events and to improve cardiac function in patients with an acute myocardial infarction. However, there is limited information on the use of intra-coronary nicorandil. A prospective randomized single center study was designed to evaluate the efficacy of the use of intra-coronary nicorandil. Subjects and Methods: Seventy-three patients with an acute ST segment elevation myocardial infarction were randomly assigned to the nicorandil group (n=37) or a control group (n=36); all patients received a PCI. In the nicorandil group of patients, 4 mg of intra-coronary nicorandil was infused directly into the infarct area prior to reperfusion (2 mg before ballooning, 2 mg before stenting). The composite endpoint was the incidence of ventricular arrhythmia, no-reflow and slow flow. We estimated the post thrombolysis in myocardial infarction (TIMI) grade, the myocardial perfusion grade after PCI and the short-term clinical outcome. Results: The baseline characteristics were similar in both groups of patients. A significant difference was observed in the composite endpoint in the nicorandil group of patients as compared to the control group of patients (p=0.037). The achievement rate of post TIMI grade 3 was significantly higher in the nicorandil group of patients (p=0.019). The myocardial perfusion grade 1 was not observed in the nicorandil group of patients; however, it was observed in five patients in the control group (p=0.019). Major adverse cardiac events in hospital and in 30 days were similar between the two groups. Conclusion: Intra-coronary nicorandil infusion reduced the occurrence of no-reflow, slow reflow, reperfusion arrhythmia and improved the myocardial perfusion grade and TIMI flow during PCI. The results of this study showed that the use of intracoronary nicorandil improved the clinical outcome in patients with an acute myocardial infarction. Background and Objectives: Intravenous nicorandil infusion with percutaneous coronary intervention (PCI) has been reported to reduce reperfusion injury events and to improve cardiac function in patients with an acute myocardial infarction. However, there is limited information on the use of intra-coronary nicorandil. A prospective randomized single center study was designed to evaluate the efficacy of the use of intra-coronary nicorandil. Subjects and Methods: Seventy-three patients with an acute ST segment elevation myocardial infarction were randomly assigned to the nicorandil group (n=37) or a control group (n=36); all patients received a PCI. In the nicorandil group of patients, 4 mg of intra-coronary nicorandil was infused directly into the infarct area prior to reperfusion (2 mg before ballooning, 2 mg before stenting). The composite endpoint was the incidence of ventricular arrhythmia, no-reflow and slow flow. We estimated the post thrombolysis in myocardial infarction (TIMI) grade, the myocardial perfusion grade after PCI and the short-term clinical outcome. Results: The baseline characteristics were similar in both groups of patients. A significant difference was observed in the composite endpoint in the nicorandil group of patients as compared to the control group of patients (p=0.037). The achievement rate of post TIMI grade 3 was significantly higher in the nicorandil group of patients (p=0.019). The myocardial perfusion grade 1 was not observed in the nicorandil group of patients; however, it was observed in five patients in the control group (p=0.019). Major adverse cardiac events in hospital and in 30 days were similar between the two groups. Conclusion: Intra-coronary nicorandil infusion reduced the occurrence of no-reflow, slow reflow, reperfusion arrhythmia and improved the myocardial perfusion grade and TIMI flow during PCI. The results of this study showed that the use of intracoronary nicorandil improved the clinical outcome in patients with an acute myocardial infarction.